ArticleCancer cell international2025
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of COQ10B in Tumor Progression and Its Association with Immune Escape in Esophageal Squamous Cell Carcinoma: A Multi-Omics and Functional Analysis.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrahepatic cholangiocarcinoma (ICC) is a primary malignant tumor of the liver, second only to hepatocellular carcinoma. The scarcity of appropriate cell lines has impeded ICC-related research. This study aims to establish a novel patient-derived ICC cell line and systematically evaluate its biological characteristics, thereby providing a valuable cellular tool for ICC research.
methodsA cell line named LPHC-6 of ICC was established using a patient-derived xenograft (PDX) tumor model. We comprehensively characterized this novel cell line through a series of techniques, including cell morphology observation, short tandem repeat (STR) analysis, karyotype analysis, cell proliferation, cell migration assays, western blot analysis, immunofluorescence staining, flow cytometry, gene mutation detection, spheroid formation assays, drug sensitivity testing, and xenograft tumor formation in nude mice.
resultsLPHC-6 cells exhibited typical characteristics of malignant epithelial cells, demonstrating robust proliferation and migration capabilities. These cells possessed a structurally complex triploid karyotype, which was confirmed to be free from cross-contamination with other human cell lines. Tumor biomarker analysis revealed positive expression of AFP and negative expression of GPC3. Additionally, LPHC-6 cells showed high expression levels of stem cell markers CD133 and CD44. The biliary epithelial cell marker CK19 was positive, whereas the hepatocyte marker Hep Par1 was negative. Genomic analysis identified an exon mutation in TP53, copy number loss in PTEN and RAD51, and copy number gain in NTRK1, PDCD1LG2, and VEGFA. Investigations confirmed that LPHC-6 cells exhibited excellent sphere formation ability and tumorigenic potential. Furthermore, LPHC-6 cells demonstrated sensitivity to Sorafenib, Lenvatinib, 5-fluorouracil, Oxaliplatin and Atezolizumab in both 2D and 3D culture system.
conclusionA novel intrahepatic cholangiocarcinoma cell line LPHC-6 has been successfully established, which provides a powerful cell tool for the research related to intrahepatic cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.